Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03599453 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 26, 2018
Last Update Posted : January 23, 2023
|
Sponsor:
Roswell Park Cancer Institute
Collaborator:
AIM ImmunoTech Inc.
Information provided by (Responsible Party):
Roswell Park Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | September 2, 2020 |
| Estimated Study Completion Date : | June 2, 2023 |